Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation

Clin Nephrol. 2005 Oct;64(4):324-6. doi: 10.5414/cnp64324.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Bone Marrow / pathology*
  • Follow-Up Studies
  • Humans
  • Imatinib Mesylate
  • Kidney Transplantation / adverse effects*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Philadelphia Chromosome
  • Piperazines / therapeutic use*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Pyrimidines / therapeutic use*
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases